Results 141 to 150 of about 962,469 (222)

Integrating Patient‐Reported Quality Measures in Systemic Lupus Erythematosus: Development of the American College of Rheumatology Implementation Guide

open access: yesArthritis Care &Research, EarlyView.
Objective To support high‐quality, patient‐centered care for systemic lupus erythematosus (SLE), the American College of Rheumatology (ACR) developed evidence‐based measures incorporating clinical and patient‐reported outcome measures (PROMs). Using the Consolidated Framework for Implementation Research (CFIR), we conducted semistructured interviews ...
Catherine Nasrallah   +13 more
wiley   +1 more source

Multilingual learning with parameter co-occurrence clustering [PDF]

open access: yes, 2011
Bane, Max   +3 more
core  

Assessing the Sensitivity and the Clinical Impact of the 2023 American College of Rheumatology/EULAR Classification Criteria in Obstetric Antiphospholid Syndrome: Findings From a Multicenter Italian Cohort With a Long‐Term Follow‐Up

open access: yesArthritis Care &Research, EarlyView.
Objective The aim of this study was to evaluate the sensitivity of the 2023 American College of Rheumatology (ACR)/EULAR classification criteria for antiphospholipid syndrome (APS) in a real‐world cohort of women diagnosed with primary obstetric APS (oAPS) and to assess their ability to identify patients at risk of future pregnancy complications ...
Francesca Ruffilli   +10 more
wiley   +1 more source

Mucocutaneous disease activity and damage accrual in systemic lupus erythematosus: analyses from the Asia‐Pacific Lupus Collaboration longitudinal cohort study

open access: yesArthritis Care &Research, Accepted Article.
Objective This research article aims to describe the prevalence, associations and health‐related quality‐of‐life (HRQoL) impact of mucocutaneous features of SLE. Methods Data from the Asia‐Pacific Lupus Collaboration cohort were analysed (2013‐2021). Mucocutaneous activity (MC‐A) items were rash, alopecia and mucosal ulcers; defined by the SLEDAI‐2K ...
Amanda M Saracino   +42 more
wiley   +1 more source

Global Analysis of the Co-Occurrence of Antimicrobial and Metal Resistance Genes in Bacterial Genomes From Dairy-Isolated Pathogens. [PDF]

open access: yesEnviron Microbiol
Almeida ACO   +8 more
europepmc   +1 more source

Cracking the Code: Which Ocular Symptoms Predict Dry Eye Signs? Insights from a large international sicca registry

open access: yesArthritis Care &Research, Accepted Article.
Purpose The study aimed to identify symptom‐based predictors of dry eye disease (DED) signs in the Sjögrens International Collaborative Clinical Alliance (SICCA) cohort. Methods Retrospective analysis examining 16 ocular symptoms (most graded 0‐4) and artificial tear (AT) use (graded 0‐3) as predictors of DED signs [abnormal ocular surface staining ...
Pragnya R Donthineni   +7 more
wiley   +1 more source

Safety of Prescription Nonsteroidal Anti‐inflammatory Drugs in Adults With Inflammatory Bowel Disease: Data From a Large Administrative Claims Cohort

open access: yesArthritis Care &Research, EarlyView.
Objective The concern that nonsteroidal anti‐inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing musculoskeletal symptoms in those with IBD, but safety data are mixed. Methods This retrospective cohort study included patients with IBD aged at least 18 years from Optum's deidentified ...
Adam S. Mayer   +4 more
wiley   +1 more source

Real‐world trends in prenatal antirheumatic drug utilization in Ontario, Canada: A cross‐sectional time‐series analysis

open access: yesArthritis Care &Research, Accepted Article.
Objectives This study aimed to describe real‐world trends in preconception and prenatal use of antirheumatic drugs among pregnant individuals with rheumatic diseases in Ontario, Canada. Methods We conducted a time‐series analysis using repeated cross‐sectional data to examine annual patterns of disease‐modifying antirheumatic drug (DMARD) use among ...
Shenthuraan Tharmarajah   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy